Summary
During the past few decades, intensive collaborative research in the fields of chronic and acute inflammatory disorders has resulted in a better understanding of the pathophysiology and diagnosis of these diseases. Modern therapeutic approaches are still not satisfactory and shock, sepsis and multiple organ failure remain the great challenge in intensive care medicine. However, the treatment of inflammatory diseases like rheumatoid arthritis, ulcerative colitis or psoriasis also represents an unresolved problem.
Many factors contribute to the complex course of inflammatory reactions. Microbiological, immunological and toxic agents can initiate the inflammatory response by activating a variety of humoral and cellular mediators. In the early phase of inflammation, excessive amounts of interleukins and lipid-mediators are released and play a crucial role in the pathogenesis of organ dysfunction. Arachidonic acid (AA), the mother substance of the pro-inflammatory eicosanoids, is released from membrane phospholipids in the course of inflammatory activation and is metabolised to prostaglandins and leukotrienes.
Various strategies have been evaluated to control the excessive production of lipid mediators on different levels of biochemical pathways, such as inhibition of phospholipase A2, the trigger enzyme for release of AA, blockade of cyclooxygenase and lipoxygenase pathways and the development of receptor antagonists against platelet activating factor and leukotrienes. Some of these agents exert protective effects in different inflammatory disorders such as septic organ failure, rheumatoid arthritis or asthma, whereas others fail to do so. Encouraging results have been obtained by dietary supplementation with long chain ω-3 fatty acids like eicosapentaenoic acid (EPA). In states of inflammation, EPA is released to compete with AA for enzymatic metabolism inducing the production of less inflammatory and chemotactic derivatives.
Article PDF
Similar content being viewed by others
References
Rola-Pleszczynski M, Thivierge M, Gagnon N, et al. Differential regulation of cytokine receptor genes by PAF, LTB4 and PGE2. J Lipid Med 1993; 6: 175–81
Weber PC. Fish oil fatty acids and cardiovascular function: epidemiology and biochemical mechanisms. Biochem Soc Trans 1990; 18: 1045–9
Neuhof H, Seeger W, Suttorp N. Activation of the pulmonary arachidonic acid system and its consequences for hemodynamics and fluid balance. In: Schlag G, Redl H, editors. First Vienna Shock Forum, Pt A: pathophysiological role of mediators and mediator inhibitors in shock. New York: Liss, 1987: 289–300
Lewis RA, Austen KF, Drazen JM, et al. Slow-reacting substance of anaphylaxis: identification of leukotriene C-1 and D from human and rat sources. Proc Natl Acad Sci USA 1980; 77: 3710–4
Fischer S, Weber PC. Prostaglandin I is formed in vivo in man after dietary eicosapentaenoic acid. Nature 1984; 307: 165–8
Lee TH, Sethi T, Crea AEG, et al. Characterization of leukotriene B3: comparison of its biological activities with leukotriene B4 and leukotriene B5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Clin Sci 1988; 74: 467–75
Lewis RA, Lee TH, Austen KF. Effects of omega-3 fatty acids on the generation of products of the 5-lipoxygenase pathway, In: Simopoulos AP, editor. Health effects of polyunsaturated fatty acids in seafoods. Orlando (FL): Academic Press, 1986: 227–38
Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B (LTB) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 1983; 117: 282–8
Sperling RI, Robin J-L, Kylander KA, et al. The effects of n-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139: 4186–91
Arni RK, Ward RJ. Phospholipase A2: a structural review. Toxicon 1996; 34: 827–41
Kramer RM, Sharp JD. Recent insight into the structure, function and biology of CPLA2. Agents Actions Suppl 1995; 46: 65–76
Glaser KB, Sung MLA, Hartman DA, et al. Cellular and topical in vivo inflammatory murine models in the evaluation of inhibitors of phospholipase A2. Skin Pharmacol 1995; 8: 300–8
Yedgar S, Dan P, Dagan A, et al. Control of inflammatory processes by cell impermeable inhibitors of phospholipase A2. Agents Actions Suppl 1995; 46: 77–84
Scott KF, Smith GM, Green JA, et al. Neutralising monoclonal antibody to human secretory phospholipase A2 is anti-hypotensive in a baboon E. coli induced septic shock model [abstract]. Prostaglandin Relat Compounds 1992: A151
Koike K, Moore EE, Moore FA, et al. Phospholipase A2 inhibition decouples lung injury from gut ischemia-reperfusion. Surgery 1992; 112: 173–80
Hosford D, Braquet P. The potential role of platelet activating factor in shock and ischemia. J Crit Care 1990; 5: 115–36
Etienne A, Hecquet F, Soulard C, et al. In. vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific platelet activating factor acether antagonist, BN 52021. Agents Actions 1985; 17: 368–70
Christmann BW, Lefferts PL, Blair IA, et al. Effect of platelet activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1990; 142: 1272–8
Miguelez R, Palacios I, Navarro F, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal 1996; 13: 35–49
Rocha FA, Andrade LE, Russo M, et al. PAF modulates eicosanoids and TNF release in immune complex arthritis in rats. J Lipid Mediat Cell Signal 1997; 16: 1–10
Hilliquin P, Guinot P, Chermat-Izard V, et al. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 1995; 22: 1651–4
Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet activating factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized, double blind, placebo controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720–8
Froon AM, Greve JW, Buurman WA, et al. Treatment with the platelet activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5: 313–9
Evans DJ, Barnes PJ, Clutzel M, et al. Effects of a potent platelet activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med 1997; 156: 11–6
Hozawa S, Haruta Y, Ishioka S, et al. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995; 152: 1198–202
Elbers ME, Gerritsen MJ, van de Kerkhof PC. The effect of topical application of the platelet activating factor antagonist RO24-0238, in psoriasis vulgaris: a clinical and immunohistochemical study. Clin Exp Dermatol 1994; 19: 453–7
Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double blind phase II trial of lexipafant, a platelet activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414–20
Seed MP, Willoughby DA. COX-2 HO NO! Cyclooxygenase-2, hemoxygenase and nitric oxide synthase: their role and interactions in inflammation. Inflamm Res 1997; 46: 279–81
Laird JMA, Herrero JF, Garcia de la Rubia P. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in monoarthritic rats: central and peripheral components. Inflamm Res 1997; 46: 203–10
Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med 1992; 372: 749–54
Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum 1997; 26 Suppl. 1. 21–7
Sheng GG, Shao J, Sheng H. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997 Dec; 113(6): 1883–91
Metz CA, Sheagren JN. Ibuprofen in animal models of septic shock. J Crit Care 1990; 5: 206–12
Bernhard GR, Wheeler AP, Russell JA. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912–8
Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671–7
Guth BD, Müller TH. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol 1997; 92: 181–90
Harris RR, Carter GW, Bell RL, et al. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol 1995; 17: 147–56
Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51
Taylor IK, OShaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI204-219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subject. Lancet 1991; 337: 690–4
Jackson DM. Obstructive airway disease: unmet needs. Meeting report. Inflamm Res 1997; 46: 242
Nickerson-Nutter CL, Medvedeff ED. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum 1996; 39: 515–21
Marder P, Spaethe SM, Froelich LL, et al. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist. Br J Clin Pharmacol 1996; 42: 457–64
Evans DJ, Barnes PJ, Spaethe SM, et al. Effect of a leukotriene B4 antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51: 1178–84
Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975; 28: 958–66
Heller A, Koch T. Omega-3 fatty acids as adjuvant therapy in inflammatory diseases. Anaesth Intensivmedizin 1996; 10: 517–28
Breil I, Koch T, Heller A, et al. Alteration of n-3 fatty acid composition in lung tissue after short-term infusion of fish oil emulsion attenuates inflammatory vascular reaction. Crit Care Med 1996; 24: 1893–902
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heller, A., Koch, T., Schmeck, J. et al. Lipid Mediators in Inflammatory Disorders. Drugs 55, 487–496 (1998). https://doi.org/10.2165/00003495-199855040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199855040-00001